Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$11.5 - $14.86 $742,647 - $959,629
-64,578 Closed
0 $0
Q2 2021

Aug 11, 2021

BUY
$13.6 - $18.98 $878,260 - $1.23 Million
64,578 New
64,578 $912,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Element Capital Management LLC Portfolio

Follow Element Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Element Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Element Capital Management LLC with notifications on news.